Historically considered undruggable, KRAS mutations have gained significant attention due to recent KRAS inhibitor clinical trials. KRAS is the most frequently mutated oncogene, occurring in approximately 20-25% of all cancers. The frequency and distribution of KRAS mutations varies depending on the type of cancer, and they are most predominant in pancreatic ductal adenocarcinoma, colorectal cancer, and non-small lung cancer.
KRAS mutations are typically considered prognostic biomarkers, as they are indicative of poor patient outcomes irrespective of treatment. KRAS mutations also commonly occur in a mutually exclusive fashion with other genetic mutations and alterations. Given this, many treatment guidelines recommend including KRAS testing in situations where molecular testing is appropriate.
Do you test for KRAS mutations at diagnosis and what method do you use? If you do not test at initial diagnosis, do you test at relapse? How do these test results play into your decision-making regarding treatment?
-
Vijay RaoMay 17, 2021Test at diagnosis and relapse with NGS.
-
Vijay RaoMay 17, 2021Test at diagnosis and relapse with NGS.
-
Vijay RaoMay 17, 2021Test at diagnosis and relapse with NGS.
-
Anonymous UserApril 29, 2021We use NGS for all advanced NSCLC, and if KRAS G12C, both TKIs are very promising. I would consider using them before Chemo immunotherapy. The issue is secondary mutations to proactively target them.
-
Anonymous UserApril 29, 2021We use NGS for all advanced NSCLC, and if KRAS G12C, both TKIs are very promising. I would consider using them before Chemo immunotherapy. The issue is secondary mutations to proactively target them.
-
Anonymous UserApril 29, 2021We use NGS for all advanced NSCLC, and if KRAS G12C, both TKIs are very promising. I would consider using them before Chemo immunotherapy. The issue is secondary mutations to proactively target them.
-
Vijay RaoApril 28, 2021I test for KRAS mutations, it is done with NGS.
-
Vijay RaoApril 28, 2021I test for KRAS mutations, it is done with NGS.
-
Vijay RaoApril 28, 2021I test for KRAS mutations, it is done with NGS.
-
Louis Sussman, NEW YORK-PRESBYTERIAN/QUEENSApril 28, 2021We test on tissue reflexively at diagnosis as part of our NGS panel. Testing at relapse is performed only on request.
-
Louis Sussman, NEW YORK-PRESBYTERIAN/QUEENSApril 28, 2021We test on tissue reflexively at diagnosis as part of our NGS panel. Testing at relapse is performed only on request.
-
Louis Sussman, NEW YORK-PRESBYTERIAN/QUEENSApril 28, 2021We test on tissue reflexively at diagnosis as part of our NGS panel. Testing at relapse is performed only on request.
-
Kimberly Canaday, ST CHARLES HEALTH SYSTEM - BENDApril 28, 2021Test all at initial diagnosis via tissue and test at relapse via liquid
-
Kimberly Canaday, ST CHARLES HEALTH SYSTEM - BENDApril 28, 2021Test all at initial diagnosis via tissue and test at relapse via liquid
-
Kimberly Canaday, ST CHARLES HEALTH SYSTEM - BENDApril 28, 2021Test all at initial diagnosis via tissue and test at relapse via liquid
-
Prabhsimranjot Singh, BRIGHAM AND WOMEN'S HOSPITALApril 27, 2021I usually test all my metastatic NSCLC with NGS and if recurrent will do liquid biopsy at the time of progression, still awaiting FDA approval of the targetable agents
-
Prabhsimranjot Singh, BRIGHAM AND WOMEN'S HOSPITALApril 27, 2021I usually test all my metastatic NSCLC with NGS and if recurrent will do liquid biopsy at the time of progression, still awaiting FDA approval of the targetable agents
-
Prabhsimranjot Singh, BRIGHAM AND WOMEN'S HOSPITALApril 27, 2021I usually test all my metastatic NSCLC with NGS and if recurrent will do liquid biopsy at the time of progression, still awaiting FDA approval of the targetable agents
-
KRAS Oncogene ConnectApril 27, 2021What are your thoughts about the treatment potential of sotorasib and adagrasib? Please share any comments, insights, concerns, or so forth.
-
KRAS Oncogene ConnectApril 27, 2021What are your thoughts about the treatment potential of sotorasib and adagrasib? Please share any comments, insights, concerns, or so forth.
-
KRAS Oncogene ConnectApril 27, 2021What are your thoughts about the treatment potential of sotorasib and adagrasib? Please share any comments, insights, concerns, or so forth.
-
Anonymous UserApril 25, 2021Test ALL patients as part of NGS, but no FDA approved therapy available until last month, so treat them with chemo +/- immunotherapy; now I will start using Sotorasib or Adagrasib;
-
Anonymous UserApril 25, 2021Test ALL patients as part of NGS, but no FDA approved therapy available until last month, so treat them with chemo +/- immunotherapy; now I will start using Sotorasib or Adagrasib;
-
Anonymous UserApril 25, 2021Test ALL patients as part of NGS, but no FDA approved therapy available until last month, so treat them with chemo +/- immunotherapy; now I will start using Sotorasib or Adagrasib;
-
Sumit SawhneyApril 24, 2021test all pts ,use immunotherapy but hoping for approval of targeted therapy soon
-
Sumit SawhneyApril 24, 2021test all pts ,use immunotherapy but hoping for approval of targeted therapy soon
-
Sumit SawhneyApril 24, 2021test all pts ,use immunotherapy but hoping for approval of targeted therapy soon
-
Ali MirmiranApril 23, 2021Yes, I now test all my patients for KRAS. If mutated, I treat with sotorasib or adagrasib.
-
Ali MirmiranApril 23, 2021Yes, I now test all my patients for KRAS. If mutated, I treat with sotorasib or adagrasib.
-
Ali MirmiranApril 23, 2021Yes, I now test all my patients for KRAS. If mutated, I treat with sotorasib or adagrasib.
-
Elan GorsheinApril 23, 2021I generally test for KRAS mutations at diagnosis through next generation sequencing, mostly for prognostic purposes.
-
Elan GorsheinApril 23, 2021I generally test for KRAS mutations at diagnosis through next generation sequencing, mostly for prognostic purposes.
-
Elan GorsheinApril 23, 2021I generally test for KRAS mutations at diagnosis through next generation sequencing, mostly for prognostic purposes.
-
Daya Sharma, MEDSTAR WASHINGTON HOSPITAL CENTERApril 23, 2021i do it in all pts as part of ngs and at relapse. drug will be available soon
-
Daya Sharma, MEDSTAR WASHINGTON HOSPITAL CENTERApril 23, 2021i do it in all pts as part of ngs and at relapse. drug will be available soon
-
Daya Sharma, MEDSTAR WASHINGTON HOSPITAL CENTERApril 23, 2021i do it in all pts as part of ngs and at relapse. drug will be available soon
-
Sherif BadawyApril 23, 2021I test for KRAS mutations at diagnosis and at relapse to inform outcomes prognosis.
-
Sherif BadawyApril 23, 2021I test for KRAS mutations at diagnosis and at relapse to inform outcomes prognosis.
-
Sherif BadawyApril 23, 2021I test for KRAS mutations at diagnosis and at relapse to inform outcomes prognosis.